PLYMOUTH - After nearly a decade in the city of Detroit, Genesis Genetics has moved its corporate headquarters to Plymouth. Tony Gordon Ph.D., Genesis Genetics Managing Director, leads the team of scientists, genetic counselors and case coordinators. In the United States, Genesis Genetics focuses its science on two important fertility technologies: Preimplantation Genetic Screening and
ANN ARBOR - Rubicon Genomics reported major gains in 2013 sales of its nucleic acid library preparation products, ThruPLEX-FD Prep Kits and PicoPLEX WGA Kits, resulting in an increase in company revenues of 85 percent. But the bioscience company did not report earnings. ?This has been a breakout year for Rubicon, as our expanded marketing
LANSING - Neogen Corp. for the second quarter of its fiscal year, which ended Nov. 30, reported lower net income despite higher sales due to what a top executive called a year of ?clean crops.? Acquisition expenses also played a part. Sales for Neogen in the quarter were $59.6 million, up 15 percent from $50.7
ANN ARBOR - Rubicon Genomics announced it has partnered with additional distributors globally to expand availability of its products that test DNA. Three new distribution partnerships have been signed for Europe. They include Amplitech for France, HPST for the Czech Republic and LuBio Science for Switzerland. Rubicon also completed new distribution agreements in Asia and
ROCHESTER HILLS - Oxford Biomedical Research has been awarded a $1,163,600 Phase 2 Small Business Innovation Research Grant by the National Institute of Environmental Health Sciences that will help Oxford develop tests designed to detect toxicity and differentiate potential toxic effects to multiple organs. GST proteins are found in many tissues and organs. They play
ANN ARBOR - HistoSonics announced Tuesday the first treatment of a patient with BPH using its Vortx RX device at the University of Michigan Department of Urology. The Vortx RX is based on histotripsy technology, a non-thermal focused ultrasound therapy that mechanically liquefies targeted tissues. The Vortx RX is an investigational device and is limited
ANN ARBOR - Once again MichBio has received a coveted invitation to attend the JPMorgan Healthcare Conference from January 13-16, 2014. As such, we would like to make some BioConnections for our member companies. ?We know that many don't have the means to attend every business development/partnering meeting out there. So, we'll "take you along"
ANN ARBOR - Appropriately assessing the potential of a product can make or break a company. All successful products fulfill an unmet market need. By understanding the market and the voice of the customer, entrepreneurs can best meet the needs of the market. Define the needs incorrectly, and all your efforts will be wasted. Come
WATERFORD - HistoSonics and its Vortx Rx medical device which uses sound energy to treat tissue inside the body without the need for traditional surgery is the Medical Main Street INNO-VATOR of the Year. The award will be given to the Ann Arbor-based company on Thursday during INNO-VENTION 2013 ? a Medical Main Street conference,
LANSING - Insurers and the Department of Financial and Insurance Services were still working Thursday to determine the effect of President Barack Obama's executive order allowing those with current health policies to retain them for at least another year. The executive order, issued after a backlash over a spate of policy cancelation notices, would allow